Wenjie Wang Selected Research

taspine

3/2017	Taspine derivative 12k suppressed A549 cell migration through the Wnt/β-catenin and EphrinB2 signaling pathway.
9/2016	A taspine derivative supresses Caco-2 cell growth by competitively targeting EphrinB2 and regulating its pathway.
11/2015	Taspine derivative TAS9 regulates cell growth and metastasis of human hepatocellular carcinoma.
3/2015	Novel taspine derivative 12k inhibits cell growth and induces apoptosis in lung cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wenjie Wang Research Topics

Disease

47	Neoplasms (Cancer) 03/2022 - 02/2011
12	Infections 10/2022 - 12/2010
12	Inflammation (Inflammations) 08/2022 - 10/2010
10	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2017
8	Carcinogenesis 01/2022 - 01/2016
7	Neoplasm Metastasis (Metastasis) 01/2021 - 11/2015
5	Hepatocellular Carcinoma (Hepatoma) 03/2022 - 01/2013
5	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2016
5	Stomach Neoplasms (Stomach Cancer) 01/2022 - 01/2018
5	Hypertension (High Blood Pressure) 08/2021 - 06/2015
4	Esophageal Squamous Cell Carcinoma 09/2021 - 10/2019
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 09/2015
4	Carcinoma (Carcinomatosis) 01/2019 - 03/2015
4	Lung Neoplasms (Lung Cancer) 01/2018 - 09/2015
4	Reperfusion Injury 10/2007 - 09/2002
4	Myocardial Ischemia (Ischemic Heart Diseases) 10/2007 - 09/2002
3	Persistent Infection 01/2022 - 01/2015
3	COVID-19 01/2022 - 10/2020
3	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 09/2016
3	Sepsis (Septicemia) 09/2019 - 01/2014
3	Fibrosis (Cirrhosis) 01/2016 - 10/2010
2	Atherosclerosis 10/2022 - 05/2005
2	Bacterial Infections (Bacterial Infection) 06/2022 - 01/2018
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2021
2	Osteoporosis 01/2022 - 06/2020
2	Leukemia 12/2021 - 02/2011
2	Melanoma (Melanoma, Malignant) 12/2021 - 01/2021
2	Lymphopenia (Lymphocytopenia) 10/2021 - 01/2021
2	Hemorrhage 08/2021 - 01/2021
2	Cardiomegaly (Heart Hypertrophy) 08/2021 - 10/2018
2	Weight Loss (Weight Reduction) 01/2021 - 02/2011
2	Cerebral Hemorrhage 12/2020 - 06/2020
2	Tuberculosis (Tuberculoses) 10/2020 - 01/2013
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 01/2018
2	Body Weight (Weight, Body) 03/2019 - 04/2015
2	Acquired Immunodeficiency Syndrome (AIDS) 02/2019 - 05/2018
2	Esophageal Neoplasms (Esophageal Cancer) 01/2019 - 01/2017

Drug/Important Bio-Agent (IBA)

20	Proteins (Proteins, Gene)FDA Link 07/2022 - 09/2002
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2012
9	Pharmaceutical PreparationsIBA 06/2022 - 01/2018
7	Biological ProductsIBA 01/2022 - 09/2002
6	CytokinesIBA 01/2021 - 01/2002
5	Long Noncoding RNAIBA 09/2021 - 01/2017
4	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2016
4	AntigensIBA 01/2021 - 02/2012
4	taspineIBA 03/2017 - 03/2015
3	Oxygen (Dioxygen)IBA 06/2022 - 01/2019
3	Anti-Bacterial Agents (Antibiotics)IBA 06/2022 - 01/2015
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2013
3	Topotecan (Hycamtin)FDA LinkGeneric 01/2022 - 12/2020
3	Angiotensin IIIBA 01/2022 - 11/2020
3	Type I DNA Topoisomerases (Topoisomerase I)IBA 10/2021 - 01/2019
3	tyrosyl-DNA phosphodiesteraseIBA 10/2021 - 09/2019
3	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2018
3	Indicators and Reagents (Reagents)IBA 01/2021 - 01/2018
3	Topoisomerase InhibitorsIBA 12/2020 - 01/2019
3	EnzymesIBA 11/2020 - 01/2019
3	Nicotinamide N-MethyltransferaseIBA 09/2020 - 10/2019
3	Messenger RNA (mRNA)IBA 01/2017 - 10/2010
3	Peroxynitrous Acid (Peroxynitrite)IBA 10/2007 - 01/2002
3	Troponin IIBA 10/2007 - 09/2002
3	Matrix Metalloproteinases (MMPs)IBA 10/2007 - 05/2003
2	CollagenIBA 10/2022 - 06/2022
2	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 10/2022 - 11/2020
2	Transcription Factors (Transcription Factor)IBA 10/2022 - 10/2021
2	Small Interfering RNA (siRNA)IBA 01/2022 - 03/2015
2	Circular RNAIBA 01/2022 - 01/2021
2	AntibodiesIBA 01/2022 - 01/2021
2	p38 Mitogen-Activated Protein KinasesIBA 12/2021 - 01/2016
2	Protein Kinases (Protein Kinase)IBA 12/2021 - 11/2020
2	Antiviral Agents (Antivirals)IBA 12/2021 - 10/2020
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2021 - 05/2017
2	Superoxide DismutaseIBA 10/2021 - 03/2019
2	AntioxidantsIBA 10/2021 - 03/2019
2	LipidsIBA 10/2021 - 07/2017
2	Tissue Plasminogen Activator (Alteplase)FDA Link 08/2021 - 01/2021
2	FibrinIBA 08/2021 - 01/2021
2	lumbrokinaseIBA 08/2021 - 01/2021
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 08/2021 - 01/2021
2	AcidsIBA 01/2021 - 01/2021
2	IronIBA 01/2021 - 11/2012
2	CateninsIBA 09/2020 - 10/2019
2	Tumor Biomarkers (Tumor Markers)IBA 03/2020 - 11/2016
2	Mitogen-Activated Protein KinasesIBA 02/2020 - 01/2016
2	FluorocarbonsIBA 02/2020 - 01/2017
2	Analgesics (Analgesic Drugs)IBA 01/2020 - 03/2016
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 09/2017
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 08/2017
2	Tyrosine Kinase InhibitorsIBA 04/2019 - 02/2019
2	NucleosidesIBA 02/2019 - 08/2017
2	Reverse Transcriptase InhibitorsIBA 02/2019 - 05/2018
2	UbiquitinIBA 01/2019 - 01/2016
2	Oncogene Proteins (Oncogene Protein)IBA 01/2019 - 10/2014

Therapy/Procedure

19	Therapeutics 06/2022 - 02/2011
6	Drug Therapy (Chemotherapy) 12/2021 - 07/2017
6	Immunotherapy 01/2021 - 01/2018
3	Ligation 08/2022 - 01/2014
3	Neoadjuvant Therapy 01/2022 - 01/2017
3	Renal Dialysis (Hemodialysis) 12/2009 - 01/2008
2	Aftercare (After-Treatment) 10/2021 - 04/2019